TY  - JOUR
AU  - Kuhnert, Robert
AU  - Sárosi, Menyhárt-Botond
AU  - George, Sven
AU  - Lönnecke, Peter
AU  - Hofmann, Bettina
AU  - Steinhilber, Dieter
AU  - Murganić, Blagoje
AU  - Mijatović, Sanja
AU  - Maksimović-Ivanić, Danijela
AU  - Hey-Hawkins, Evamarie
PY  - 2017
UR  - http://doi.wiley.com/10.1002/cmdc.201700309
UR  - https://radar.ibiss.bg.ac.rs/handle/123456789/2789
AB  - The progression of cancer is accelerated by increased proliferation, angiogenesis, and inflammation. These processes are mediated by leukotrienes. Several cancer cell lines overexpress 5-lipoxygenase, an enzyme that converts arachidonic acid into leukotrienes. An early inhibitor of the 5-lipoxygenase pathway is Rev-5901, which, however, lacks in invivo efficacy, as it is rapidly metabolized. We investigated the introduction of carboranes as highly hydrophobic and metabolically stable pharmacophores into lipoxygenase inhibitors. Carboranes are icosahedral boron clusters that are remarkably stable and used to increase the metabolic stability of unstable pharmaceutics without changing their biological activity. By introduction of meta-carborane into Rev-5901, the first carborane-based inhibitor of the 5-lipoxygenase pathway was obtained. We report the synthesis and inhibitory and cytotoxic behavior of these compounds toward several melanoma and colon cancer cell lines and their related anticancer mechanisms.
T2  - ChemMedChem
T1  - CarbORev-5901: The First Carborane-Based Inhibitor of the 5-Lipoxygenase Pathway
IS  - 13
VL  - 12
DO  - 10.1002/cmdc.201700309
SP  - 1081
EP  - 1086
ER  - 

@article{
author = "Kuhnert, Robert and Sárosi, Menyhárt-Botond and George, Sven and Lönnecke, Peter and Hofmann, Bettina and Steinhilber, Dieter and Murganić, Blagoje and Mijatović, Sanja and Maksimović-Ivanić, Danijela and Hey-Hawkins, Evamarie",
year = "2017",
abstract = "The progression of cancer is accelerated by increased proliferation, angiogenesis, and inflammation. These processes are mediated by leukotrienes. Several cancer cell lines overexpress 5-lipoxygenase, an enzyme that converts arachidonic acid into leukotrienes. An early inhibitor of the 5-lipoxygenase pathway is Rev-5901, which, however, lacks in invivo efficacy, as it is rapidly metabolized. We investigated the introduction of carboranes as highly hydrophobic and metabolically stable pharmacophores into lipoxygenase inhibitors. Carboranes are icosahedral boron clusters that are remarkably stable and used to increase the metabolic stability of unstable pharmaceutics without changing their biological activity. By introduction of meta-carborane into Rev-5901, the first carborane-based inhibitor of the 5-lipoxygenase pathway was obtained. We report the synthesis and inhibitory and cytotoxic behavior of these compounds toward several melanoma and colon cancer cell lines and their related anticancer mechanisms.",
journal = "ChemMedChem",
title = "CarbORev-5901: The First Carborane-Based Inhibitor of the 5-Lipoxygenase Pathway",
number = "13",
volume = "12",
doi = "10.1002/cmdc.201700309",
pages = "1081-1086"
}

Kuhnert, R., Sárosi, M., George, S., Lönnecke, P., Hofmann, B., Steinhilber, D., Murganić, B., Mijatović, S., Maksimović-Ivanić, D.,& Hey-Hawkins, E.. (2017). CarbORev-5901: The First Carborane-Based Inhibitor of the 5-Lipoxygenase Pathway. in ChemMedChem, 12(13), 1081-1086.
https://doi.org/10.1002/cmdc.201700309

Kuhnert R, Sárosi M, George S, Lönnecke P, Hofmann B, Steinhilber D, Murganić B, Mijatović S, Maksimović-Ivanić D, Hey-Hawkins E. CarbORev-5901: The First Carborane-Based Inhibitor of the 5-Lipoxygenase Pathway. in ChemMedChem. 2017;12(13):1081-1086.
doi:10.1002/cmdc.201700309 .

Kuhnert, Robert, Sárosi, Menyhárt-Botond, George, Sven, Lönnecke, Peter, Hofmann, Bettina, Steinhilber, Dieter, Murganić, Blagoje, Mijatović, Sanja, Maksimović-Ivanić, Danijela, Hey-Hawkins, Evamarie, "CarbORev-5901: The First Carborane-Based Inhibitor of the 5-Lipoxygenase Pathway" in ChemMedChem, 12, no. 13 (2017):1081-1086,
https://doi.org/10.1002/cmdc.201700309 . .